Katherine Van Loon, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Katherine Van Loon, MD, MPH

Assistant Clinical Professor, University of California, San Francisco

Phone: (415) 353-9888
Box 1770, UCSF
San Francisco, CA 94143-1770

View on UCSF Profiles

Cancer Center Membership

Associate Member » Cancer Control

Education

Duke University    B.S.    05/00    Biology
Yale University    M.P.H.    05/02    Health Policy
Medical College of Georgia    M.D.    05/06    Medicine
Beth Israel Deaconess, Harvard Medical School    Intern    06/07    Internal Medicine
Beth Israel Deaconess, Harvard Medical School    Resident    06/09    Internal Medicine
University of California, San Francisco    Fellow    06/12    Oncology
 


Professional Experience

  • 2012-present
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF
  • 2011-2012
    Non-ACGME Fellow, Division of Hematology/Oncology, UCSF
  • 2009-2011
    ACGME Fellow, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2013
    NANETS Clinical Investigator Scholarship
  • 2013
    AHRQ K12 PARTNERS Program Scholar
  • 2012
    Young Investigator Award, ASCO Conquer Cancer Foundation
  • 2008
    Yale/Johnson & Johnson Physician Scholar in International Health, South Africa
  • 2008
    Nomination by Harvard Medical School Class of 2008 for Excellence in Teaching
  • 2002
    Dean’s Prize for Outstanding MPH Thesis, Yale University
  • 2001
    Weinerman Fellowship for Social Justice, Yale University
  • 2000
    Graduation with Distinction in Biology, Duke University
  • 2000
    Howard Hughes Undergraduate Fellowship in Neuroscience, Duke University

Selected Publications

  1. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  2. The incidence of oesophageal cancer in Eastern Africa: Identification of a new geographic hot spot? Cancer Epidemiol. 2015 Apr; 39(2):143-9.
    View on PubMed
  3. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015 Mar; 4(1):9-17.
    View on PubMed
  4. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
    View on PubMed
  5. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014 Jul 25.
    View on PubMed
  6. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View on PubMed
  7. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6.
    View on PubMed
  8. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol. 2014 Apr 1; 32(10):991-6.
    View on PubMed
  9. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park). 2013 Aug; 27(8):758, 763.
    View on PubMed
  10. Gene Profiling in Colon Cancer: How to Integrate Profiling into Practice. Personalized Medicine in Oncology. 2013; 2(4):204-11.
    View on PubMed
  11. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013 Jun; 12(2):95-102.
    View on PubMed
  12. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. J Natl Compr Canc Netw. 2012 Nov 1; 10(11):1379-86.
    View on PubMed
  13. Metastatic colorectal cancer: a curable disease. Oncology (Williston Park). 2012 Mar; 26(3):275-6, 282.
    View on PubMed
  14. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012 Feb; 137(2):310-5.
    View on PubMed
  15. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol. 2011 Jul; 23(4):403-9.
    View on PubMed
  16. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13288-93.
    View on PubMed

Go to UCSF Profiles, powered by CTSI